Skip to main content

Cerus Value Stock - Dividend - Research Selection

Cerus

ISIN: US1570851014 , WKN: 905249

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System is based on its proprietary technology for controlling biological replication; and targets and inactivates blood-borne pathogens, such as viruses, bacteria, and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, and red blood cell transfusion products. The company\'s INTERCEPT Blood Systems for platelets and plasma are designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; and INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion. It markets platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was founded in 1991 and is headquartered in Concord, California.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Tracking Baker Brothers Portfolio - Q2 2025 Update

2025-09-15
Baker Brothers’ Q2 2025 13F portfolio increased to $10.31B, with holdings highly concentrated in a few biotech names. Read more about the portfolio here.

Discover Promising Penny Stocks This August 2025

2025-08-27
As of late August 2025, the U.S. stock market has shown resilience, with major indices closing higher despite political uncertainties and upcoming earnings reports from key players like Nvidia. In such a climate, investors often seek opportunities beyond the well-trodden paths of large-cap stocks. Penny stocks—typically representing smaller or newer companies—remain an intriguing option for those looking to uncover potential growth at a lower entry cost. While the term may seem dated, these...

The German National Blood Advisory Committee Issues Formal Recommendation for Improving the Safety of Platelet Transfusions

2025-08-25
CONCORD, Calif., August 25, 2025--Cerus Corporation (Nasdaq: CERS) announced today the publication of a new recommendation from the German National Blood Advisory Committee (Arbeitskreis Blut or AK Blut), which recommends proactive measures, including pathogen inactivation (PI) such as INTERCEPT®, as core measures to enhance the safety of platelet transfusions. AK Blut is an expert committee that advises the German federal authorities on the safety of blood, blood products, and cells for transfu

Cerus Corporation to Participate in the Cantor Global Healthcare Conference 2025

2025-08-21
CONCORD, Calif., August 21, 2025--Cerus Corporation (Nasdaq: CERS) announced today that company management will participate in a fireside chat at the Cantor Global Healthcare Conference 2025 on Wednesday, September 3, 2025, at 10:55 A.M. ET.

Cerus Corporation (NASDAQ:CERS) Just Reported And Analysts Have Been Cutting Their Estimates

2025-08-09
NasdaqGM:CERS 1 Year Share Price vs Fair Value Explore Cerus's Fair Values from the Community and select yours...

Cerus Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

2025-08-07
NasdaqGM:CERS 1 Year Share Price vs Fair Value Explore Cerus's Fair Values from the Community and select yours Cerus...

Cerus: Q2 Earnings Snapshot

2025-08-05
CERS) on Tuesday reported a loss of $5.7 million in its second quarter. On a per-share basis, the Concord, California-based company said it had a loss of 3 cents. The biomedical products company posted revenue of $52.4 million in the period.

Cerus Corporation (CERS) Q2 2025 Earnings Call Transcript

2025-08-05
Cerus Corporation (NASDAQ:CERS) Q2 2025 Earnings Conference Call August 5, 2025 4:30 PM ETCompany ParticipantsKevin D.

Cerus Corporation Announces Second Quarter 2025 Financial Results

2025-08-05
CONCORD, Calif., August 05, 2025--Cerus Corporation (Nasdaq:CERS) announced financial results for the second quarter ended June 30, 2025, and provided a business update.

Cerus Corporation to Release Second Quarter 2025 Financial Results on August 5, 2025

2025-07-22
CONCORD, Calif., July 22, 2025--Cerus Corporation (Nasdaq: CERS) announced today that its second quarter 2025 financial results will be released on Tuesday, August 5, 2025, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET, during which management will discuss the Company’s financial results and provide a general business overview and outlook.